PEN

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025. Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025. Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025. Gross profit margin of 67.9% in the second quarter of 2026, an increase of 1.9% compared to the second quarter of 2025. Total operating expenses of $223.9 million in the second quarter of 2026, comprised of R&D of $25.4 million and SG&A of $198.5 million, which includes $6.9 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $41.0 million and net income of $34.8 million in the second quarter of 2026. Full Year 2026 Financial Outlook and Webcast and Conference Call InformationGiven the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026. About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X. Forward-Looking StatementsExcept for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Investor RelationsPenumbra, [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-second-quarter-2026-financial-results-302838410.html

It has been about a month since the last earnings report for Penumbra (PEN). Shares have lost about 1.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Penumbra, Inc. before we dive into how investors and analysts have reacted as of late. Penumbra reported first-quarter 2026 earnings per share (EPS) of 82 cents, a penny lower than the year-ago quarter. The figure missed the Zacks Consensus Estimate by 26.1%. Penumbra registered revenues of $374.8 million in the reported quarter, up 15.6% year over year. The figure topped the Zacks Consensus Estimate by 1.4%. In the reported quarter, Penumbra’s gross profit improved 17.4% year over year to $253.4 million. The gross margin expanded 102 basis points (bps) to 67.6% despite a 12.1% rise in the cost of revenues. Selling, general and administrative expenses rose 25.6% to $192.8 million. Research and development expenses totaled $22.4 million, up 1.4% year over year. Operating profit amounted to $38.2 million compared with $40.4 million in the corresponding period of 2025. The adjusted operating margin contracted 225 bps year over year to 10.2%. Penumbra exited the first quarter of 2026 with cash and marketable investments of $615.7 million compared with $544.8 million at the end of 2025. Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions. Currently, Penumbra has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Penumbra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Penumbra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, IQVIA Holdings (IQV), has gained 4.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026. IQVIA reported revenues of $4.15 billion in the last reported quarter, representing a year-over-year change of +8.4%. EPS of $2.90 for the same period compares with $2.70 a year ago. IQVIA is expected to post earnings of $3.03 per share for the current quarter, representing a year-over-year change of +7.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.3%. IQVIA has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026. Full Year 2026 Financial Outlook and Webcast and Conference Call Information Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Investor Relations Penumbra, Inc. [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2026-financial-results-302764359.html

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -25.91%. A quarter ago, it was expected that this medical device maker would post earnings of $1.12 per share when it actually produced earnings of $1.18, delivering a surprise of +5.36%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Penumbra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $374.76 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $324.14 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Penumbra shares have added about 4.2% since the beginning of the year versus the S&P 500's gain of 6%. While Penumbra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Penumbra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.19 on $385.82 million in revenues for the coming quarter and $5.08 on $1.59 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. DarioHealth Corp. (DRIO), another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 13. This company is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +40.8%. The consensus EPS estimate for the quarter has been revised 4.7% higher over the last 30 days to the current level. DarioHealth Corp.'s revenues are expected to be $5.57 million, down 17.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report DarioHealth Corp. (DRIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Boston Scientific beat expectations in Q1 with organic sales up 9.4%, revenue of $5.203 billion and adjusted EPS of $0.80, while adjusted operating margin was 28%. Management trimmed guidance, cutting full-year organic growth to 6.5–8% and raising full-year adjusted EPS to $3.34–3.41, citing near-term pressure from WATCHMAN, electrophysiology (EP) and Urology (WATCHMAN volumes softened beginning mid‑February). Capital priorities remain strategic tuck‑in M&A and buybacks: the board added $4 billion to reach $5 billion in repurchase authorization with ~$2 billion planned for Q2, the company expects about $4 billion of 2026 free cash flow, and the Penumbra acquisition is still targeted to close in the second half of 2026 pending approvals. Interested in Boston Scientific Corporation? Here are five stocks we like better. Why Boston Scientific's Big Dip Could Be a Bigger Opportunity Boston Scientific (NYSE:BSX) reported first-quarter 2026 results that landed near the top end of management’s prior guidance, while executives reduced their outlook for the remainder of the year citing “unanticipated headwinds” and changing business patterns in several key franchises. Chairman and CEO Mike Mahoney said the company delivered “a solid quarter,” with total company organic sales growth of 9.4% versus a guidance range of 8.5% to 10%. Boston Scientific posted adjusted EPS of $0.80, up 6% year over year and at the high end of its $0.78 to $0.80 range. Adjusted operating margin was 28%. → Credo Stock Flashes Strong Bullish Signal—Upswing Just Starting Beware the Death Cross: 3 Stocks Triggering This Spooky Signal CFO Jon Monson said first-quarter revenue totaled $5.203 billion, representing 11.6% reported growth versus the prior year and including a 220 basis point foreign exchange tailwind ($104 million). Excluding FX, operational and organic revenue growth both came in at 9.4%. On profitability, Monson said adjusted gross margin was 70.5%, down 100 basis points year over year, “primarily driven by tariffs as well as inventory charges related to the discontinuation of our PolarX cryoablation system.” → Allbirds Exits Shoes, Pivots to AI With NewBird Rebrand 3 Healthcare Stocks Using AI to Drive Growth Despite the first-quarter performance, Mahoney said the year “has proven to be a more challenging year than we initially expected,” prompting the company to guide for organic growth of 5% to 7% in the second quarter and reduce full-year organic growth guidance to 6.5% to 8%. Boston Scientific guided to second-quarter adjusted EPS of $0.82 to $0.84 and updated its full-year adjusted EPS outlook to $3.34 to $3.41, which management said implies 9% to 11% growth. Monson added that the EPS outlook includes an approximate $0.04 FX headwind for the year. → Amazon Stock Up 30%: Is AMZN Still a Buy Before Earnings? During Q&A, Mahoney said the guidance reduction was “primarily EP, WATCHMAN, and Urology,” adding that the company “started to see declining WATCHMAN volume for the first time” beginning in mid-February, that EP share trends were weaker than anticipated, and that Urology underperformed expectations. WATCHMAN: Mahoney said the company saw “a strong increase in concomitant growth and a deceleration of standalone WATCHMAN,” and that growth came in below internal expectations. Electrophysiology (EP): Mahoney said the EP business delivered a strong quarter but that the company “did lose a bit more share than we anticipated,” leading Boston Scientific to “anticipate greater share erosion” in guidance. Urology: Mahoney said Urology faced challenges in stone management and sacral neuromodulation, with “commercial model disruption” affecting the pelvic health franchise. Mahoney said U.S. sales grew 11%, with double-digit growth in five of eight business units. EMEA grew 1% operationally, with growth driven by FARAPULSE, Coronary and Vascular therapies, and Neuromodulation, offset by the discontinuation of ACURATE and PolarX, which “largely” impacted EMEA. Asia-Pac grew 12% operationally, led by Japan and China. Mahoney also said the company accelerated the timing of the PolarX cryocatheter discontinuation “given some recent safety events and the availability of non-thermal ablation technologies.” By business, he cited: Urology: Organic sales growth of 1%, with headwinds from China’s VBP, product gaps in the core stone portfolio, and continued sacral neuromodulation disruption. Mahoney pointed to FDA approval for Asurys and additional planned 2026 launches, including a slim ureteroscope later in the year. He also said the Valencia Technologies acquisition, which closed in April, adds eCoin tibial nerve stimulation and should support improvement as commercial capabilities stabilize. Endoscopy: Organic sales growth of 7%, including better-than-anticipated performance from AXIOS as supply and product size availability improved. Mahoney cautioned that second-quarter results will still reflect AXIOS impacts and other “transient supply chain disruptions,” with improvement expected in the second half. Neuromodulation: Organic sales growth of 15%, with Mahoney highlighting Intracept performance and adoption in DBS of Cartesia X leads and the Illumina 3D programming algorithm. Cardiovascular: Organic sales growth of 11%. Interventional Cardiology/Vascular Therapies grew 8% organically, driven by double-digit coronary therapies growth and imaging momentum. Vascular Therapies grew 7% organically, driven by TCAR and Varithena, offset by the China VBP impact on arterial business that management expects to annualize in the second quarter. Interventional oncology grew 15% organically, and Mahoney said the company received FDA clearance for “Any Day Dosing” enabled by the TheraSphere 360 Y-90 management platform. Cardiac rhythm management (CRM): Sales declined 3%, with impacts Mahoney attributed to a “physician advisory,” tough comparisons in low-voltage device change-outs, and Middle East conflict-related disruption on the high-voltage side. He said the company expects CRM to return to growth in the second quarter and to post low single-digit growth for the full year, supported by the U.S. launch of EluPro. Mahoney said WATCHMAN grew 19% organically in the first quarter but “was below our expectations,” with U.S. volumes pressured as the quarter progressed. He attributed the trend to annualizing an initial concomitant adoption tailwind, as well as a softening in standalone cases tied to “hospital capacity, related procedure prioritization, and evolving reimbursement dynamics.” Mahoney discussed CHAMPION-AF data presented at ACC, calling it supportive of the long-term opportunity. Chief Medical Officer Ken Stein said the study “hit all of its primary safety and efficacy endpoints and all of the important secondary endpoints,” and added that updates to labeling, guidelines, and national coverage determination “just takes time to play through.” For 2026, Mahoney said Boston Scientific now expects global WATCHMAN growth in the mid-teens, with low- to mid-teens growth in the U.S. and more than 20% internationally. He said concomitant procedures represented roughly 25% of WATCHMAN cases today and that the company still expects that mix to rise over the long-range period, even as standalone procedures face near-term pressure. In EP, Mahoney said organic sales rose 22% in the quarter, including 18% in the U.S. and 30% internationally. However, management reduced its 2026 EP outlook, with Mahoney saying Boston Scientific now expects the global EP business to grow approximately 10%, including mid-single digit growth in the U.S. and about 20% internationally. He cited competitive dynamics in PFA, mentioning Medtronic, Johnson & Johnson, and Abbott. Monson said the company expects full-year 2026 adjusted gross margin to be “slightly below” 2025, citing lower-than-expected product mix benefit and incremental investments in supply chain and quality systems. Still, he reiterated an expectation for 50 to 75 basis points of adjusted operating margin expansion in 2026 driven by OpEx leverage, spend controls, and efficiency initiatives. Boston Scientific posted $170 million in free cash flow in Q1 and now expects about $4 billion of free cash flow for full-year 2026. As of March 31, the company had $1.453 billion in cash and a gross debt leverage ratio of 1.8x. Monson said the company’s top capital allocation priority remains “strategic tuck-in M&A, followed by share repurchase.” He noted the board approved an additional $4 billion for the share repurchase program, bringing total authorization to $5 billion. While the company has been restricted from repurchasing shares, Monson said it intends to buy back approximately $2 billion in the second quarter, subject to conditions and securities laws, funded through cash on hand and projected cash generation during the quarter. On the previously announced agreement to acquire Penumbra, management reiterated that guidance excludes the deal. Mahoney said Boston Scientific anticipates closing the transaction in the second half of 2026, subject to the Penumbra shareholder vote on May 6 (referenced elsewhere on the call as May 7) and remaining regulatory clearances. Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery. Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales. The article "Boston Scientific Q1 Earnings Call Highlights" was originally published by MarketBeat.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Penumbra (NYSE:PEN) and its peers. The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs. The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.5%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 14% since the latest earnings results. Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions. Penumbra reported revenues of $385.4 million, up 22.1% year on year. This print exceeded analysts’ expectations by 4.8%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ revenue and EPS estimates. Penumbra scored the biggest analyst estimates beat and fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 2.9% since reporting and currently trades at $329.90. Is now the time to buy Penumbra? Access our full analysis of the earnings results here, it’s free. Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems (NASDAQ:MMSI) manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy. Merit Medical Systems reported revenues of $393.9 million, up 10.9% year on year, outperforming analysts’ expectations by 1%. The business had a strong quarter with a beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 17.7% since reporting. It currently trades at $67.82. Is now the time to buy Merit Medical Systems? Access our full analysis of the earnings results here, it’s free. Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE:AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Artivion reported revenues of $116 million, up 19.2% year on year, falling short of analysts’ expectations by 0.8%. It was a slower quarter as it posted EPS in line with analysts’ estimates and a slight miss of analysts’ revenue estimates. Artivion delivered the highest full-year guidance raise but had the weakest performance against analyst estimates in the group. As expected, the stock is down 17.7% since the results and currently trades at $33.46. Read our full analysis of Artivion’s results here. Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ:ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings. ICU Medical reported revenues of $535.9 million, down 13.8% year on year. This print topped analysts’ expectations by 1%. Overall, it was a strong quarter as it also produced a beat of analysts’ EPS estimates and a narrow beat of analysts’ full-year EPS guidance estimates. ICU Medical had the slowest revenue growth among its peers. The stock is down 17.8% since reporting and currently trades at $123.03. Read our full, actionable report on ICU Medical here, it’s free. Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure? These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. StockStory’s analyst team — all seasoned professional investors — uses quantitative analysis and automation to deliver market-beating insights faster and with higher quality.

It has been about a month since the last earnings report for Penumbra (PEN). Shares have lost about 1.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Penumbra, Inc. before we dive into how investors and analysts have reacted as of late. Penumbra, Inc. (PEN) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%. GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period. For the full year, adjusted EPS was $3.84, up 82.9% year over year. Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%. For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER). The company reports under two geographical segments — the United States and International. PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis. Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues). The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access. The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER. Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER. In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues. Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit amounted to $59.2 million compared with $42.8 million in the corresponding period of 2024. The adjusted operating margin expanded 181 bps year over year to 13.4%. Penumbra exited the fourth quarter of 2025 with cash and marketable investments of $544.8 million compared with $340.1 million at the end of 2024. In January 2026, Penumbra announced a definitive agreement to be acquired by Boston Scientific in a cash and stock transaction, valuing the company at $374 per share or approximately $14.5 billion in enterprise value. The transaction is expected to be completed in 2026, subject to PEN stockholders’ approval and the satisfaction of other customary closing conditions. In light of this proposed acquisition, Penumbra stopped providing financial guidance for full-year 2026. Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions. At this time, Penumbra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Penumbra has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Penumbra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Integer (ITGR), has gained 0.1% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025. Integer reported revenues of $472.06 million in the last reported quarter, representing a year-over-year change of +5%. EPS of $1.76 for the same period compares with $1.43 a year ago. For the current quarter, Integer is expected to post earnings of $1.21 per share, indicating a change of -7.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -9.2% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Integer. Also, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Penumbra, Inc. PEN reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%. GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period. For the full year, adjusted EPS came in at $3.84, up 82.9% year over year. Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%. For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER). Since the Feb. 25 announcement, PEN shares have risen 1.7%, closing at $344.39 on Friday. The company reports under two geographical segments — the United States and International. PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis. Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues). Penumbra, Inc. price-consensus-eps-surprise-chart | Penumbra, Inc. Quote The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access. The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER. Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER. In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues. Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit came in at $59.2 million compared with $42.8 million in the comparable 2024 period. The adjusted operating margin expanded 181 bps year over year to 13.4%. Penumbra exited the fourth quarter of 2025 with cash and marketable investments of $544.8 million compared with $340.1 million at the end of 2024. In January 2026, Penumbra announced a definitive agreement to be acquired by Boston Scientific in a cash and stock transaction, valuing the company at $374 per share or approximately $14.5 billion in enterprise value. The transaction is expected to be completed in 2026, subject to PEN stockholders’ approval and the satisfaction of other customary closing conditions. In light of this proposed acquisition, Penumbra stopped providing financial guidance for full-year 2026. Penumbra exited the fourth quarter of 2025 with better-than-expected earnings and revenues. Sales growth of global thrombectomy products, and global embolization and access products were both driven by the U.S. performance. The expansion of both margins is also highly encouraging. During the quarter, the company announced results from the landmark STORM-PE randomized controlled trial, which found that the use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy, with anticoagulation achieved a superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism. Findings also showed significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes. Currently, Penumbra carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Cardinal Health CAH and Align Technology ALGN. Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%. Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%. CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%. Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%. ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Penumbra (PEN) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.36%. A quarter ago, it was expected that this medical device maker would post earnings of $0.9 per share when it actually produced earnings of $0.97, delivering a surprise of +7.78%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Penumbra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $385.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.74%. This compares to year-ago revenues of $315.52 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Penumbra shares have added about 9.2% since the beginning of the year versus the S&P 500's gain of 0.7%. While Penumbra has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Penumbra was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.12 on $370.67 million in revenues for the coming quarter and $5.06 on $1.58 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, InspireMD, Inc. (NSPR), is yet to report results for the quarter ended December 2025. This company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -15.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. InspireMD, Inc.'s revenues are expected to be $2.74 million, up 40.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report InspireMD, Inc. (NSPR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research